Drug Trial Radar · NCT06659640
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
89
Actual
Start
Nov 7, 2024
Primary completion
Jan 5, 2028
Study completion Jun 22, 2028
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Oct 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT
Conditions
- Hereditary Hemorrhagic Telangiectasia
Interventions
ALN-6400Drug
ALN-6400 will be administered subcutaneously (SC)
PlaceboDrug
Placebo will be administered subcutaneously (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Frequency of Adverse EventsTime frame: Up to Week 36
- Part B: Frequency of Adverse EventsTime frame: Up to Week 96
Locations
16 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Birmingham, Alabama
Clinical Trial Site
Cypress, California
Clinical Trial Site
Gainesville, Florida
Clinical Trial Site
Indianapolis, Indiana
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
St Louis, Missouri
Clinical Trial Site
Chapel Hill, North Carolina
Clinical Trial Site
Camperdown, Australia
Clinical Trial Site
Parkville, Australia
Clinical Trial Site
Mount Royal, Canada
Clinical Trial Site
Toronto, Canada
Clinical Trial Site
Bordeaux, France
Clinical Trial Site
Bron, France
Clinical Trial Site
Homburg, Germany
Clinical Trial Site
L'Hospitalet de Llobregat, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.